

检索证明

经检索《Science Citation Index Expanded》(SCI-EXPANDED)数据库、《Journal Citation Reports》(JCR)数据库和《中国科学院文献情报中心期刊分区表升级版》，以下 1 篇文献的收录简要信息、期刊的影响因子及分区如下：

标题: PMA exerts anti-leukemia effect in Ph+ ALL through activating PKC δ and its downstream molecules

作者: Wang, X (Wang, Xu); Tan, JF (Tan, Jinfeng); Tang, J (Tang, Jie); Wang, T (Wang, Teng); Zeng, DC (Zeng, Dachuan); Zheng, RR (Zheng, Renren); Hu, J (Hu, Jing); Liu, ST (Liu, Suotian); Wei, W (Wei, Wei); Zou, J (Zou, Jie); Du, Y (Du, Yan); Huang, ZL (Huang, Zhenglan); Gao, M (Gao, Miao)

来源出版物: CANCER CELL INTERNATIONAL 卷:25 期:1 DOI:10.1186/s12935-025-04013-4 出版时间:OCT 21 2025

Web of Science 核心合集中的“被引频次”: 0 次

期刊《[CANCER CELL INTERNATIONAL](#)》2024 年影响因子为 6.0。

经检索《中国科学院文献情报中心期刊分区表升级版》，2025 年分区如下：

刊名	Cancer Cell International		
年份	2025		
ISSN/EISSN	1475-2867/1475-2867		
Review	否		
OA Journal Index (OAJ)	否		
Open Access	是		
Web of Science	SCIE		
	学科	分区	Top 期刊
小类	ONCOLOGY 肿瘤学	3	
大类	医学	3	否

特此证明
(详细内容见附件)



扫描二维码查看报告

郑州大学图书馆
教育部科技查新工作站 Z12
检索人: 荆啸一
2025 年 11 月 06 日



注: 因 JCR 数据更新滞后, 新出版论文的期刊影响因子以最新版 JCR 数据为参考。

第 1 条, 共 1 条

标题: PMA exerts anti-leukemia effect in Ph+ ALL through activating PKC δ and its down-stream molecules

作者: Wang, X (Wang, Xu);Tan, JF (Tan, Jinfeng);Tang, J (Tang, Jie);Wang, T (Wang, Teng);Zeng, DC (Zeng, Dachuan);Zheng, RR (Zheng, Renren);Hu, J (Hu, Jing);Liu, ST (Liu, Suotian);Wei, W (Wei, Wei);Zou, J (Zou, Jie);Du, Y (Du, Yan);Huang, ZL (Huang, Zhenglan);Gao, M (Gao, Miao)

来源出版物: CANCER CELL INTERNATIONAL 卷: 25 期: 1 DOI: 10.1186/s12935-025-04013-4 出版年: OCT 21 2025

Web of Science 核心合集中的 "被引频次": 0

被引频次合计: 0

使用次数 (最近 180 天): 0

使用次数 (2013 年至今): 0

引用的参考文献数: 55

摘要: BackgroundPhiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is a subtype of precursor B ALL in genetics and is recognized as a subclass with poor prognosis. Tyrosine kinase inhibitors (TKIs) greatly improve the prognosis of Ph+ ALL patients. However, the long-term survival rate is still low (with a 3-year survival rate only 55%). Hence, it is urgent to explore new therapies to improve prognosis for Ph+ ALL patients. Protein kinase C (PKC) is proven to be a tumor suppressor in recent years. Activation of PKC by its novel agonist PMA reverts the malignancy of many hematological diseases. However, the effect of PMA on Ph+ ALL is unclear.MethodsWe investigated the biological effects of PMA on Ph+ ALL cells and the potential mechanism in this study. In this study, the SUP-B15 and BP190 cell lines were subjected to PMA treatment. Cell proliferation, cycle distribution, apoptosis, protein expression levels, and gene expression changes were assessed using CCK-8 assay, flow cytometry, Western blot analysis, DAPI staining, and quantitative real-time PCR. Additionally, bone marrow mononuclear cells were isolated for further investigation, and RNA sequencing was conducted on SUP-B15 cells. Furthermore, the mouse model was established to evaluate the in vivo biological effects of PMA.ResultsWe found that PMA could promote apoptosis, inhibit proliferation and promote differentiation of human Ph+ ALL cells. More importantly, we demonstrated for the first time that these effects caused by PMA were related to the activation of PKC delta and its down-stream molecules, such as p-ERK, p21 and so on. ConclusionsPMA exerts an anti-leukemia effect in Ph+ ALL by activating PKC delta and its downstream molecules, thereby demonstrating its potential as a therapeutic agent for Ph+ ALL.

入藏号: WOS:001597424100001

PubMed ID: 41121078

语言: English

文献类型: Article

作者关键词: Philadelphia chromosome;Acute lymphoblastic leukemia;PMA;PKC;p-ERK

KeyWords Plus: PROTEIN-KINASE-C; CELL-CYCLE ARREST; DIFFERENTIATION; CANCER; INDUCTION; PHOSPHORYLATION; INHIBITION; MUTATIONS; PATHWAY; REVEAL

地址: [Wang, Xu; Gao, Miao] Chongqing Med Univ, Affiliated Hosp 1, Dept Lab Med, Chongqing, Peoples R China;[Wang, Xu] North Henan Med Univ, Sch Lab Med, Xinxiang 453500, Henan, Peoples R China;[Tan, Jinfeng; Tang, Jie; Zheng, Renren; Hu, Jing; Liu, Suotian; Wei, Wei; Zou, Jie; Du, Yan; Huang, Zhenglan] Chongqing Med Univ, Dept Clin Hematol, Key Lab Lab Med Diagnost Designated, Minist Educ, Chongqing, Peoples R China;[Wang, Teng] Chongqing Med Univ, Affiliated Hosp 2, Dept Hematol, Chongqing, Peoples R China;[Zeng, Dachuan] Chongqing Med Univ, Women & Childrens Hosp, Dept Clin Lab, Chongqing, Peoples R China;[Zeng, Dachuan] Chongqing Hlth Ctr Women & Children, Dept Clin Lab, Chongqing, Peoples R China

通讯作者地址: [Gao, Miao] (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Lab Med, Chongqing, Peoples R China;[Huang, Zhenglan] (corresponding author), Chongqing Med Univ, Dept Clin Hematol, Key Lab Lab Med Diagnost Designated, Minist Educ, Chongqing, Peoples R China

电子邮件地址: ;;;;;;;;;;zhenglan@cqmu.edu.cn;waters@hospital.cqmu.edu.cn

出版商:BMC

出版商地址: CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Web of Science Index : 《Science Citation Index Expanded》 (SCI-EXPANDED)

Web of Science 类别:Oncology

研究方向:Oncology

IDS 号:8UE3H

eISSN: 1475-2867

来源出版物页码计数: 17

基金资助致谢:This work was supported by 2023 Outstanding Young Teachers Program of Sanquan College of Xinxiang Medical University (to Xu Wang, Grant numbers [SQ2023YQJH08]).This work was supported by The Natural Science Foundation of Chongqing (to Jing Hu, Grant numbers [CSTB2022NSCQ-MSX0764]) and Program for Youth Innovation in Future Medicine, Chongqing Medical University (to Jing Hu, Grant numbers [W0012]).

基金资助机构	授权号
The 2023 Outstanding Young Teachers Program of Sanquan College of Xinxiang Medical University	SQ2023YQJH08
Natural Science Foundation of Chongqing	CSTB2022NSCQ-MSX0764
Program for Youth Innovation in Future Medicine, Chongqing Medical University	W0012

ESI 高被引论文: N

ESI 热点论文: N

输出日期: 2025 年 11 月 06 日